Novartis Pays $19.9 Million to Settle Elidel Off-Label Claims

As Bloomberg reported on October 30th, 2012, Novartis agreed to pay $19.9 million to the U.S. and Texas in settlement of claims it unlawfully marketed Elidel (case no. 06-3213, Pennsylvania Eastern District Court). Elidel was approved by the FDA in 2001 for the treatment of itchy, scaly, inflamed skin conditions such as eczema and atopic dermatitis. According to the lawsuit, Novartis required its sales representatives to induce doctors to prescribe Elidel in children younger than two years of age for uses not approved by the FDA. Now, AttorneyOne.com, a recognized authority on law, can provide helpful, proven advice and simple solutions including how to get in contact with legal counsel so anyone can easily and inexpensively deal with cases of Elidel severe adverse events. [http://www.attorneyone.com/elidel/

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Elidel: severe adverse events threat

Elidel: severe adverse events threat

Novartis required its sales representatives to induce doctors to prescribe Elidel in children younger than two years of age for uses not approved by the FDA

San Diego, CA (PRWEB) November 16, 2012

The media spotlight is often a double-edged sword. No one knows this better than people who suffer from Elidel severe adverse events. And yet, gossip and rumor-mongering aside, the real story here is being overlooked according to Sean Burke of AttorneyOne.

As Bloomberg reported on October 30th, 2012, Novartis agreed to pay $19.9 million to the U.S. and Texas in settlement of claims it unlawfully marketed Elidel (case no. 06-3213, Pennsylvania Eastern District Court). Elidel was approved by the FDA in 2001 for the treatment of itchy, scaly, inflamed skin conditions such as eczema and atopic dermatitis. According to the lawsuit, Novartis required its sales representatives to induce doctors to prescribe Elidel in children younger than two years of age for uses not approved by the FDA.

Plaintiff Donald R. Galmines, a former Novartis medical representative, alleges fraudulent schemes by Novartis to increase the market share of Elidel, by means of an aggressive campaign to promote Elidel for off-label use in children under the age of two and its systematic payment of kickbacks to physicians as financial incentive to induce them to prescribe Elidel for off-label use.

AttorneyOne.com, a recognized authority on law, can provide helpful advice and simple solutions including how to get in contact with legal counsel so that, in case of severe adverse events from Elidel, someone can easily and inexpensively deal with it. As Mr. Burke, director of Media Relations for AttorneyOne.com, added, “What all this information really illustrates is that threat from Elidel remains. For that reason, our focus should squarely fall on getting the word out and assisting people in finding the right legal assistance.”

In January 2006, the FDA approved updated labeling for Elidel including a boxed warning about a possible risk of cancer. Use of Elidel in children under 2 years of age is not recommended.
AttorneyOne.com has further information on Elidel lawsuits including how to get in contact with legal counsel.

Headquartered in San Diego, CA Attorney One was founded in 2004 and is not a law firm. They offer a nationwide legal service which helps consumers find the best representation for their legal needs. You can learn more about Attorney One at our website http://www.attorneyone.com. You can also find us on Facebook at http://www.facebook.com/AttorneyOne. Checkout earlier news from us at http://www.prweb.com/releases/2012/11/prweb10120721.htm.